30
Participants
Start Date
March 11, 2025
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2025
Triazolam and TS-172
Oral single administration of triazolam 0.25 mg at single administration phase, followed by a oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration phase
TS-172 and itraconazole
Oral single administrtation of TS-172 20 mg at single administration phase, followed by a oral single administration of TS-172 and itoraconazole 200 mg at concomitant administration phase
Taisho Pharmaceutical Co., Ltd selected site, Tokyo
Taisho Pharmaceutical Co., Ltd.
INDUSTRY